中國生物科技服務(08037.HK):上海隆耀獲評為專精特新中小企業
格隆匯5月9日丨中國生物科技服務(08037.HK)公吿,上海市經濟和信息化委員會最近已根據《上海市優質中小企業梯度培育管理實施細則》公佈2024年上海市專精特新中小企業名單,其中,公司間接非全資附屬公司上海隆耀生物科技有限公司獲認定為2024年上海市專精特新中小企業。
專精特新中小企業,是指具備專業化、精細化、特色化、新穎化特點,在技術、市場、品質、效益等方面表現突出的中小企業。其為上海市優質企業梯度培育體系的重要部分。
上海隆耀獲評為專精特新中小企業,為公司致力於嵌合抗原受體T細胞(CAR-T)治療領域的長期發展及持續創新的重大認可。有關評價使上海隆耀成為將獲得上海市經濟和信息化委員會更多資源及政策支持的重要實體。其亦將提升上海隆耀的研究和開發能力,增加其品牌知名度,並增強其在CAR-T治療領域的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.